Regeneron's Inmazeb approved by FDA to treat Ebola virus infection on 14 October 2020

 Report by : Gan Yung Chyan, KUCINTA SETIA

Image : Web Screenshot (Regeneron Pharmaceuticals)

According to US' Food & Drug Administration (FDA), it has officially approved the commercial use of Inmazeb to treat Ebola virus infection on 14 October 2020. 

Marketed by Regeneron Pharmaceuticals, Inmazeb is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn). It is the first FDA-approved treatment for Ebola virus infection in adult and pediatric patients.

Side-effects of taking Inmazeb include any common symptom of Ebola virus infection including fever, chills, fast heart rate, fast breathing and vomiting. FDA advises users to discontinue treatment in case of a hypersensitivity reaction.

Ebola virus, a coronavirus in the same family as SARS-CoV-2, is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, with surface and materials such as bedding and clothing, contaminated with fluids.

Ref:

FDA Approves First Treatment for Ebola Virus, https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus